Premium
Time from incident primary cancer until recurrence or second primary cancer: Risk factors and impact in general practice
Author(s) -
Rasmussen Linda Aagaard,
Jensen Henry,
Virgilsen Line Flytkjær,
Falborg Alina Zalounina,
Møller Henrik,
Vedsted Peter
Publication year - 2019
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.13123
Subject(s) - medicine , cancer , endometrial cancer , comorbidity , incidence (geometry) , cancer registry , population , ovarian cancer , primary care , breast cancer , oncology , family medicine , environmental health , physics , optics
Objective Specialised follow‐up care after cancer treatment is changing towards increased involvement of general practice. To ensure timely detection of new cancer events, knowledge is warranted on the timing of cancer recurrence (CR) and second primary cancer (SPC), including risk factors for CR. Methods This population‐based register study included 67,092 patients diagnosed with malignant melanoma, bladder, lung, ovarian, endometrial, colorectal and breast cancer in Denmark in 2008–2016. The time from primary cancer to CR or SPC and risk factors for prolonged time to CR were analysed and stratified on sex and primary cancer type. Results Cancer recurrence proportions ranged from 6% to 35%. The risk of CR increased profoundly within the first 3 years and then levelled off, except for breast cancer. A total of 3%–6% of patients had SPC, with monotonously increasing cumulative incidence proportions. Besides primary tumour characteristics, lower educational level, living alone and comorbidity were associated with earlier CR. For example, in female malignant melanoma, HRs and 95% confidence intervals were 0.47 (0.37–0.61) for high educational level, 1.40 (1.16–1.68) for living alone and 2.38 (1.53–3.70) for high comorbidity. Conclusion The results may inform stratified risk assessment in decision of frequency, location and duration of post‐cancer follow‐up care.